ViroGates 대차 대조표 상태

재무 상태 기준 확인 3/6

ViroGates 의 총 주주 지분은 DKK7.1M 이고 총 부채는 DKK5.3M, 이는 부채 대 자기자본 비율을 74.8% 로 가져옵니다. 총자산과 총부채는 각각 DKK14.1M 및 DKK7.0M 입니다.

주요 정보

74.8%

부채 비율

DKK 5.30m

부채

이자 보상 비율	n/a
현금	DKK 7.43m
주식	DKK 7.09m
총 부채	DKK 6.97m
총 자산	DKK 14.06m

최근 재무 상태 업데이트

Recent updates

ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans

Mar 06

We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely

Nov 21

Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?

Jun 14

We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate

Sep 19

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

Apr 14

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

Dec 30

재무 상태 분석

단기부채: VIRO 의 단기 자산 ( DKK13.9M )이 단기 부채( DKK1.7M ).

장기 부채: VIRO 의 단기 자산( DKK13.9M )이 장기 부채( DKK5.3M ).

부채 대 자본 내역 및 분석

부채 수준: VIRO 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: VIRO 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 74.8% 로 증가했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: VIRO 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 7 %의 역사적 비율로 계속 증가할 경우 VIRO 의 현금 활주로는 1년 미만입니다.

ViroGates 대차 대조표 상태

재무 상태 기준 확인 3/6

주요 정보

최근 재무 상태 업데이트

ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely

Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?

We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

Recent updates

Third quarter 2024 earnings released

New major risk - Revenue size

ViroGates A/S Maintains Earnings Guidance for the Full-Year of 2024

Second quarter 2024 earnings released

First quarter 2024 earnings released

Full year 2023 earnings released

ViroGates A/S to Report Fiscal Year 2023 Results on Mar 21, 2024

New major risk - Shareholder dilution

ViroGates A/S has filed a Follow-on Equity Offering in the amount of DKK 15.077282 million.

Third quarter 2023 earnings released

ViroGates A/S Announces Positive Results from a Randomized Controlled Clinical Trial on Supar-Guided Antibody Treatment in Sepsis

Virogates Provides Earnings Guidance for 2023

Second quarter 2023 earnings released

New major risk - Market cap size

First quarter 2023 earnings released

Full year 2022 earnings released

ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans

ViroGates A/S Announces CE-IVD approval for suPARnostic® TurbiLatex on the Roche Diagnostics cobas® Pure and Pro instrument platforms

ViroGates A/S Announces Chief Financial Officer Changes

ViroGates A/S to Report Fiscal Year 2022 Results on Mar 23, 2023

ViroGates A/S Announces Executive Changes

We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely

ViroGates A/S Announces the Publication of A New Study That Shows SsuPAR upar Causes Cardiovascular Disease

ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform

Second quarter 2022 earnings released

ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023

Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?

High number of new directors

ViroGates A/S Announces Board Changes

ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product, Suparnostic® Poc+

First quarter 2022 earnings released

ViroGates A/S announces successful finalization of the development project with DIESSE Diagnostica Senese S.p.A

Third quarter 2021 earnings released

We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate

Second quarter 2021 earnings released

ViroGates A/S and the Hellenic Institute for the Study of Sepsis Announce Positive Top-Line Results from the Save-More Study

First quarter 2021 earnings released: kr.1.37 loss per share (vs kr.2.04 loss in 1Q 2020)

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

ViroGates A/S Announces Clinical Routine Use in Greece

New 90-day high: kr.94.00

ViroGates A/S Announces a New Private Hospital as Clinical Routine Customer in Spain

ViroGates A/S Announces Initiation of A Clinical Trial with Hiss to Clinically Validate Its Commercial Biomarker Test for Guiding Early Anakinra Treatment of Covid-19 Patients Across 42 Hospitals

ViroGates A/S Announces Delay in the Development and Launch of suPARnostic POC+ Product

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

ViroGates A/S to Report Q3, 2021 Results on Nov 11, 2021

ViroGates A/S to Report Q2, 2021 Results on Aug 19, 2021

ViroGates Announces Receipt of the First Order from Mikkeli Central Hospital in Finland

New 90-day high: kr.67.50

Third quarter earnings released

Virogates Announces Receipt of A First Order from the University Hospital of Salamanca, A New Clinical Routine Customer in Spain

New 90-day low - kr.57.00

First half earnings released

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기